From the PR Newswire

ROCKVILLE, Md., Sept. 24, 2012 — Neuralstem, Inc. announced that President and CEO Richard Garr will present at the 2012 Aegis Healthcare Conference on Friday, September 28 at 10:00 a.m. PT. Garr will discuss the company’s opportunities in neural stem cell therapy and neurogenic drugs. He will provide an update on the company’s ongoing clinical trials: NSI-566/amyotrophic lateral sclerosis (ALS) and NSI-189/major depressive disorder, and an overview on future trials.

# # #

The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is an all-volunteer 501(c)(3)charity. 100% of all funds raised go to building awareness, treatment research and development, plus ALS family assistance. There are no administrative costs.

Contributions are tax-deductible.

You may also be interested in visiting the RASCALS Store.

The material presented here is for informational purposes only and should not be construed as medical advice, or relied upon as a substitute for medical advice from a health care provider.

—